Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment

(2015) Johanna Svensson et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Analysis of 177Lu-DOTA-Octreotate Therapy-Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors

(2015) D. Denoyer et al.   JOURNAL OF NUCLEAR MEDICINE

177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study

(2014) Giovanni Paganelli et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

(2014) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors

(2014) Ebrahim S. Delpassand et al.   PANCREAS

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours

(2013) Amir Sabet et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2013) A. Sabet et al.   JOURNAL OF NUCLEAR MEDICINE

Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

(2012) Santosh K. Gupta et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment

(2012) M. Sandstrom et al.   JOURNAL OF NUCLEAR MEDICINE

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy

(2011) Jean-Mathieu Beauregard et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

(2011) Stephan Walrand et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland

(2011) Andreas Klaus Pfeifer et al.   NEUROENDOCRINOLOGY

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy

(2010) Michael Garkavij et al.   CANCER

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy

(2010) Ludovic Ferrer et al.   CANCER

Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors

(2010) M. van Essen et al.   JOURNAL OF NUCLEAR MEDICINE

[177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney

(2010) Christina Swärd et al.   WORLD JOURNAL OF SURGERY

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

(2009) Flavio Forrer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate

(2009) Mattias Sandström et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma

(2009) S. E. Buckley et al.   JOURNAL OF NUCLEAR MEDICINE

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy

(2008) Michael Lassmann et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY